SINGAPORE (Reuters) – AstraZeneca said on Friday it will supply Singapore with its COVID-19 antibody cocktail, Evusheld, by the end of the year.

Evusheld can act as another layer of protection, alongside vaccines, for people who are at high risk of COVID-19 infection, according to AstraZeneca’s statement.

The company did not specify how many courses of the treatment would be supplied to the Southeast Asian city-state.

The U.S. Food and Drug Administration on Wednesday authorised the use of Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.

(Reporting by Chen Lin in Singapore; Editing by Ed Davies)